Pharmaceuticals
Exceptional Performance for Ureteral Stents: ICP DAS-BMP Reveals Latest TPU Materials at CMEF 2025
HSINCHU, March 25, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a committedTaiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is excited to announce its participation in CMEF (China International Medical Equipment Fair), held fromApril 8-11, 2025,...
2025-03-25 09:45
2357
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximatelyRMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reachedRMB820.5 million, a 50.3% YoY growth, with a net pr...
2025-03-24 23:09
3165
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximatelyRMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reachedRMB820.5 million, a 50.3% YoY growth, with a net pr...
2025-03-24 22:54
3468
WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024
* Revenue increased by 90.8% YoY to RMB 4,052 million * Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023 * Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of 26.4%, a 13.0 percentag...
2025-03-24 22:45
3238
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically...
2025-03-24 22:30
1795
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
NEW YORK, March 24, 2025 /PRNewswire/ -- On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068)—received Fast Track Des...
2025-03-24 21:00
1591
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025
NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing Phase I clinical trial of ...
2025-03-24 20:30
1889
SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
BEIJING, March 24, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) appl...
2025-03-24 20:00
3247
GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia
* Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ruxolitinib * Nearly all myelofibrosis patients globally are estimated to develop anaemia over the course of the disease, and over 30% will discontinue treatment due to ...
2025-03-24 10:00
2034
ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China
SHANGHAI, March 24, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity disorder (ADHD). This milestone represents a substant...
2025-03-24 09:00
2746
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. T...
2025-03-24 08:15
2217
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
SAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
2025-03-24 08:00
2612
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
HONG KONG, March 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onMarch 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical trial approval from the U.S. Food and Drug Administrati...
2025-03-24 08:00
2122
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019
-- U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform -- -- Evaluation of SCB-1019 as part of a respiratory combination Trimer-Tagged PreF vaccine (RSV + hMPV ± PIV3...
2025-03-24 07:56
2112
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14
* EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical development. * Preclinical highlights： * EVM14 induced a dose-dependent, antigen-specific immun...
2025-03-24 07:30
2532
Syneron Bio Announces Strategic Collaboration with AstraZeneca
BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of chronic ...
2025-03-21 20:02
2423
Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up
SHANGHAI and HONG KONG, March 21, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period endingDecember 31, 2024, along with several significant milestones achieved in recent months. Dr. Jay Mei, Antengene's Founder,...
2025-03-21 19:29
4451
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target...
2025-03-21 19:10
5183
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, ki...
2025-03-21 08:38
2173
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
* Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) * Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2...
2025-03-21 08:30
1934
Week's Top Stories
Most Reposted
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 276 media titles]
2026-01-01 10:00
Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 260 media titles]
2025-12-29 14:27Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
7388
